Alembic Pharma: Unhealthy headwind

Alembic Pharma: Unhealthy headwind

Alembic Pharmaceuticals share price fell over 4% intraday to Rs 757 after the company reported a weak set of numbers for the quarter ended September 2021.
On November 10, Alembic Pharmaceuticals reported 49.2% fall in its Q2 net profit at Rs 169.29 crore against Rs 333.37 crore and revenue was down 11.3% at Rs 1,292.32 crore versus Rs 1,457.10 crore, YoY.
Earnings before interest, tax, depreciation and amortization (EBITDA) was down 42% at Rs 257.2 crore versus Rs 443.5 crore and margin was down at 19.9% versus 30.4%, YoY.

The Q2 revenue was 3% above estimates but EBITDA/profit miss estimates by 6%/8%.
US business continued to decline while India business performed well. The management’s cost rationalisation programme blunted by increased freight cost.
Meanwhile, the company informed that the United States Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals’ Injectable Facility (F-3) located at Karkhadi from October 28, 2021 to November 10, 2021.

The USFDA issued a Form 483 with 10 observations.
None of the observations are related to data integrity and management believes that they are addressable.
The drug maker is preparing the response to the observations, which will be submitted to the USFPA. It is committed to maintain the highest quality standards and compliance at all times.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.